GlassScriptPhysician profile
Cheryl S Citron
NPI 1235168386
$5,022.45
in general payments reported to CMS, 2019-2025
35 companies · $725 in 2025
The $725 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $665 · 2021: $384 · 2022: $666 · 2023: $877 · 2024: $1,260 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,663 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,662.59 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $746.24 | 2019-2022 | |
| Dermavant Sciences, INC. | $484.00 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $438.77 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $383.49 | 2019-2025 | Winlevi, Blu-U, Odomzo |
| Allergan, INC. | $358.19 | 2020-2022 | |
| Incyte Corporation | $343.38 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $264.49 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Janssen Biotech, INC. | $249.20 | 2023-2024 | Tremfya, Simponi, Simponi Aria |
| Leo Pharma INC. | $225.49 | 2019-2024 | Adbry |
| Kerecis Limited | $214.59 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Pfizer INC. | $196.30 | 2019-2024 | |
| Vyne Pharmaceuticals INC. | $192.51 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $122.02 | 2022-2025 | Sotyktu |
| Abbvie INC. | $85.73 | 2023-2025 | |
| Organon LLC | $70.52 | 2025 | Vtama |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $59.16 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $58.09 | 2021-2024 | Arazlo, Duobrii, Jublia |
| Ucb, INC. | $46.17 | 2023 | Bimzelx |
| Convatec INC. | $45.77 | 2025 | |
| Verrica Pharmaceuticals INC. | $45.06 | 2024 | Ycanth |
| Biofrontera INC. | $45.00 | 2019 | |
| Sandoz INC. | $43.75 | 2020-2021 | |
| Blueprint Medicines Corporation | $42.45 | 2023-2024 | Ayvakit |
| Lilly USA, LLC | $38.09 | 2023-2024 | Ebglyss, Taltz |
| Botanix Sb INC | $36.22 | 2025 | Sofdra |
| Celgene Corporation | $32.33 | 2024-2025 | Sotyktu |
| Amgen INC. | $30.37 | 2022-2024 | Otezla |
| Mission Pharmacal Company | $18.96 | 2021 | |
| Revance Therapeutics, INC. | $16.36 | 2025 | Daxxify |
| Arcutis Biotherapeutics, INC. | $16.18 | 2024 | Zoryve |
| Almirall LLC | $15.86 | 2022 | |
| Journey Medical Corporation | $15.32 | 2023 | |
| Sebela Pharmaceuticals INC. | $14.99 | 2020 | |
| Glenmark Therapeutics INC. | $14.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Citron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.